# Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

> **NCT02319837** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 1068 (actual)

## Conditions studied

- Hormone Sensitive Prostate Cancer
- Prostate Cancer
- Cancer of the Prostate

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Placebo (No longer applicable in Open Label study period)
- **DRUG:** Leuprolide Open Label

## Key facts

- **NCT ID:** NCT02319837
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-12-17
- **Primary completion:** 2023-01-31
- **Final completion:** 2026-09-19
- **Target enrollment:** 1068 (ACTUAL)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02319837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02319837, "Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT02319837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*